Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [21] Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study
    El Husseini, Kinan
    Piton, Nicolas
    De Marchi, Marielle
    Gregoire, Antoine
    Vion, Roman
    Blavier, Pierre
    Thiberville, Luc
    Baste, Jean-Marc
    Guisier, Florian
    CANCERS, 2021, 13 (19)
  • [22] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [23] Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
    Huang, Qingyuan
    Zhang, Hua
    Hai, Josephine
    Socinski, Mark A.
    Lim, Eric
    Chen, Haiquan
    Stebbing, Justin
    ONCOIMMUNOLOGY, 2018, 7 (12):
  • [24] The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
    Ichihara, Eiki
    Harada, Daijiro
    Inoue, Koji
    Sato, Ken
    Hosokawa, Shinobu
    Kishino, Daizo
    Watanabe, Kazuhiko
    Ochi, Nobuaki
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    LUNG CANCER, 2020, 139 : 140 - 145
  • [25] Impact of air pollution on the progress-free survival of non-small cell lung cancer patients with anti-PD-1/PD-L1 immunotherapy: A cohort study
    Liu, Bin
    Jiang, Meijie
    Wu, Yuhua
    Zheng, Pai
    Gao, Xu
    Wang, Jinghui
    ENVIRONMENTAL POLLUTION, 2025, 368
  • [26] Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer
    Wang, Xiaoming
    Chen, Dayu
    Ma, Yuyan
    Mo, Dongping
    Yan, Feng
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (08) : 1934 - 1943
  • [27] Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer
    Hirakawa, Tetsu
    Yamaguchi, Kakuhiro
    Funaishi, Kunihiko
    Shimoji, Kiyofumi
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Yamada, Shingo
    Hattori, Noboru
    CANCERS, 2025, 17 (04)
  • [28] Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression
    Pourmir, Ivan
    Elaidi, Reza
    Maaradji, Zineb
    De Saint Basile, Hortense
    Ung, Monivann
    Ismaili, Mohammed
    Fournier, Laure
    Rance, Bastien
    Gibault, Laure
    Ben Dhiab, Rym
    Gazeau, Benoit
    Fabre, Elizabeth
    CANCERS, 2023, 15 (23)
  • [29] Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy
    Li, Mengqian
    Gan, Lu
    Song, Andrew
    Xue, Jianxin
    Lu, You
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 323 - 330
  • [30] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Dantoing, Edouard
    Piton, Nicolas
    Salaun, Mathieu
    Thiberville, Luc
    Guisier, Florian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
12345